Spire Healthcare Group plc (LON:SPI - Get Free Report) rose 13.4% on Friday . The company traded as high as GBX 256.50 ($3.48) and last traded at GBX 245.50 ($3.33). Approximately 40,970,105 shares changed hands during mid-day trading, an increase of 2,397% from the average daily volume of 1,640,628 shares. The stock had previously closed at GBX 216.50 ($2.93).
Analysts Set New Price Targets
SPI has been the subject of several research analyst reports. Berenberg Bank reaffirmed a "buy" rating and set a GBX 280 target price on shares of Spire Healthcare Group in a research note on Thursday, July 31st. JPMorgan Chase & Co. reduced their target price on Spire Healthcare Group from GBX 309 to GBX 303 and set an "overweight" rating for the company in a research note on Tuesday, August 5th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat, Spire Healthcare Group currently has an average rating of "Buy" and a consensus price target of GBX 294.33.
Check Out Our Latest Stock Analysis on SPI
Spire Healthcare Group Stock Up 13.4%
The business has a fifty day simple moving average of GBX 218.25 and a 200 day simple moving average of GBX 203.40. The firm has a market cap of £987.82 million, a price-to-earnings ratio of 5,336.96, a PEG ratio of 1.06 and a beta of 0.96. The company has a debt-to-equity ratio of 62.25, a current ratio of 0.70 and a quick ratio of 0.74.
Spire Healthcare Group (LON:SPI - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported GBX 4.10 EPS for the quarter. Spire Healthcare Group had a return on equity of 3.82% and a net margin of 1.96%. As a group, equities analysts forecast that Spire Healthcare Group plc will post 15.6634747 EPS for the current fiscal year.
Spire Healthcare Group Company Profile
(
Get Free Report)
Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Spire Healthcare Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spire Healthcare Group wasn't on the list.
While Spire Healthcare Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.